Atherosclerosis and folic acid supplementation trial in chronic renal failure: Baseline results
| Autor: | Barry P McGrath, Robert J. Walker, Sonya Ristevski, Robert C. Atkins, Gavin J. Becker, Brian Hutchison, Pauline Branley, Sophia Zoungas, Lisa L Demos, Christine Muske, John J McNeil, Margaret B. Fraenkel, Peter G. Kerr |
|---|---|
| Předmět: |
Adult
Male medicine.medical_specialty Arteriosclerosis Placebo-controlled study Fibrinogen Cobalamin law.invention chemistry.chemical_compound Folic Acid Randomized controlled trial law Internal medicine Diabetes mellitus medicine Humans cardiovascular diseases Pulse wave velocity Aged Aged 80 and over Creatinine business.industry General Medicine Middle Aged medicine.disease Compliance (physiology) Endocrinology chemistry Nephrology cardiovascular system Cardiology Kidney Failure Chronic Female business medicine.drug |
| Zdroj: | Monash University |
| Popis: | SUMMARY: Background: Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) is a randomized placebo controlled trial assessing whether high-dose folic acid can reduce cardiovascular events and atherosclerosis progression in patients with chronic renal failure (CRF). Here we report the baseline results and compare indices of arterial structure (carotid intima-medial thickness (IMT)) and function (systemic arterial compliance (SAC)), pressure augmentation index (AI x ) and pulse wave velocity (PWV a-f and PWV f-d)) to age- and sex-matched controls. Methods: Three hundred and fifteen subjects with CRF (serum creatinine ≥ 0.40 mmol/L) aged 24‐ 79 years (mean ± SD: 56.6 ± 13.6 years) and 213 healthy controls (58.2 ± 10.2 years) were studied. Fasting blood samples were assayed for lipids (both groups), total homocysteine (tHcy), red cell folate, cobalamin and fibrinogen (CRF group). Ultrasound B mode measurements were used to determine mean carotid IMT and applanation tonometry techniques to determine SAC, AI x , PWV (a-f), PWV (f-d) and central pressures. Results: Ninety-six per cent of the CRF group had at least one of: hypertension, hypercholesterolaemia, diabetes or smoking; 35% had established cardiovascular disease. The mean IMT was greater in CRF patients than in controls (0.86 ± 0.19 vs 0.68 ± 0.11 mm, P < 0.001). The SAC was significantly lower, and PWV (a-f) and AI x significantly higher. The tHcy was increased in 97% of the CRF group (27.3 ± 2.9 m mol/L (normal < 13)). Total homocysteine did not correlate with IMT or any other measure of arterial function. However, those in the upper quantile of tHcy ( ≥ 25 m mol/L) did have higher PWV (a-f) and lower SAC than those in the lower quantile. Conclusions: Compared to normals, patients with CRF exhibited a 10‐15-year shift to the right in age-related increases in carotid IMT and PWV (a-f), and significantly increased central pressure augmentation. This 5-year study is examining the impact of high-dose folic acid therapy on cardiovascular end-points, IMT progression and arterial function in CRF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|